首页> 外文期刊>Journal of Medicinal Chemistry >Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)–Ligand Interactions on Living Cancer Cells
【24h】

Ligand-Based NMR Study of C-X-C Chemokine Receptor Type 4 (CXCR4)–Ligand Interactions on Living Cancer Cells

机译:基于配体的C-X-C趋化因子受体4(CXCR4) - 活性癌细胞相互作用的NMR研究

获取原文
获取原文并翻译 | 示例
       

摘要

Peptide-binding G protein-coupled receptors (GPCRs) are key effectors in numerous pathological and physiological pathways. The assessment of the receptor-bound conformation of a peptidic ligand within a membrane receptor such as a GPCR is of great impact for a rational drug design of more potent analogues. In this work, we applied multiple ligand-based nuclear magnetic resonance (NMR) methods to study the interaction of peptide heptamers, derived from the C-X-C Motif Chemokine 12 (CXCL12), and the C-X-C Chemokine Receptor Type 4 (CXCR4) on membranes of human T-Leukemia cells (CCRF-CEM cells). This study represents the first structural investigation reporting the receptor-bound conformation of a peptide to a GPCR directly on a living cell. The results obtained in the field of CXCL12/CXCR4 are proofs of concept, although important information for researchers dealing with the CXCR4 field arises. General application of the presented NMR methodologies is possible and surely may help to boost the development of new therapeutic agents targeting GPCRs.
机译:肽结合G蛋白偶联受体(GPCR)是在许多病理和生理途径关键效应物。膜受体中的肽配体,如GPCR的受体结合构象的评估是用于合理的药物设计更有效的类似物的影响很大。在这项工作中,我们应用了多种基于配体的核磁共振(NMR)的方法来研究肽七聚体的相互作用,从CXC基序趋化因子12(CXCL12)导出的,并且对人的膜上的CXC趋化因子受体类型4(CXCR4) T-白血病细胞(CCRF-CEM细胞)。这项研究是第一个结构性的调查直接在活细胞报告肽的受体结合的构象与GPCR。在CXCL12 / CXCR4领域获得的结果是概念验证,虽然对付CXCR4领域的研究人员的重要信息出现。所提出的方法核磁共振一般应用是可能的,肯定可以帮助提高的新的治疗药物靶向GPCR的发展。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2018年第7期|共14页
  • 作者单位

    Dipartimento di Farmacia Università di Napoli Federico II 80131 Naples Italy;

    Istituto di Biostrutture e Bioimmagini C.N.R. 80134 Naples Italy;

    Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania “Luigi Vanvitelli” 81100 Caserta Italy;

    Dipartimento di Farmacia Università di Napoli Federico II 80131 Naples Italy;

    Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania “Luigi Vanvitelli” 81100 Caserta Italy;

    Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania “Luigi Vanvitelli” 81100 Caserta Italy;

    Dipartimento di Scienze e Tecnologie Ambientali Biologiche e Farmaceutiche Università degli Studi della Campania “Luigi Vanvitelli” 81100 Caserta Italy;

    Molecular Immunology and Immunoregulation Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS-Napoli 80131 Naples Italy;

    Molecular Immunology and Immunoregulation Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS-Napoli 80131 Naples Italy;

    Molecular Immunology and Immunoregulation Istituto Nazionale Tumori “Fondazione G. Pascale” IRCCS-Napoli 80131 Naples Italy;

    Dipartimento di Farmacia Università di Napoli Federico II 80131 Naples Italy;

    Dipartimento di Farmacia Università di Napoli Federico II 80131 Naples Italy;

    Dipartimento di Farmacia Università di Napoli Federico II 80131 Naples Italy;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号